A complete application in a minute
Tailored resume and cover letter, ready to send.
The International Centre for Cancer Vaccine Science at the University of Gdańsk invites applications for a Research Assistant to join the Structural Proteomics group. The role supports clinical trial and R&D activities under the SWIFT project, focusing on cancer biology and immunotherapy.
We seek candidates with a Master’s degree (or equivalent) in bioinformatics/biotechnology or related fields, excellent communication skills, good English, and motivation to pursue a doctoral thesis.
Organisation/Company University of Gdansk Department International Centre for Cancer Vaccine Science Research Field Technology » Biotechnology Researcher Profile First Stage Researcher (R1) Positions Master Positions Application Deadline 9 Nov 2026 - 23:59 (Europe/Warsaw) Country Poland Type of Contract Temporary Job Status Full-time Hours Per Week 40 Offer Starting Date 1 Dec 2026 Is the job funded through the EU Research Framework Programme? Other EU programme Is the Job related to staff position within a Research Infrastructure? No
We are looking for aResearch Assistant to work in the International Centre for Cancer Vaccine Science (ICCVS) hosted by the University of Gda ń sk in one of the research groups: Structural Proteomics (dr hab. U. Kalathiya). Role in the project: Scientific / scientific-technical staff members.
The position is offered in the frame of the project No. FENG.02.01-IP.05-0031/23 "Science for Welfare, Innovations, and Forceful Therapies (SWIFT)". The project is implemented under the International Research Agenda program financed by the European Funds for a Smart Economy 2021-2027 (FENG), Priority FENG.02 Innovation-friendly environment, Measure FENG.02.01 International Research Agendas.
About the SWIFT project
ICCVS is the Center of Excellence established in 2017 as part of the IRAP programme of FNP at the University of Gdańsk. Since then, we have elaborated an algorithm for identification of cancer specific T cells, which selectively kill autologous tumour but not healthy lung tissue. Simultaneously, we have developed the method for identification and quantification of cancer specific antigens (neoantigens) presented by MHC class I molecules of the tumour. Therefore, in the current project we want to use this experience and know-how to develop comprehensive anti-cancer therapy that will be translated into clinical trial and will open new research pathways in oncology. To achieve this goal the current project is composed of the following 2 parts which will be developed in parallel: 1). Clinical Trial and 2) Research and Development Activities focused on improvement of the approach tested in clinical trial. With the SWIFT project we aim to stream R&D activity into the following directions: 1). Identification of neoantigens presented by the tumour MHC class I and class II molecules and isolation of T cell clones that recognize them (groups involved: Clinical Peptidomics, Cancer Immunology, Structural Peptidomics and Immune Memory & Cell Reprogramming) 2). Determination of specific receptor-ligand pairs responsible for docking of cancer derived extracellular vesicles (EVs) to T cells (groups involved: Clinical Peptidomics, Structural Proteomics and Cancer Immunology) 3). Development of the strategies preventing T cell reprogramming by cancer derived EVs (groups involved: Immune Memory & Cell Reprogramming, Structural Proteomics and Cancer Immunology) 4). Modification of tumour microenvironment with reprogrammed autologous monocytes (groups involved: Immune Memory & Cell Reprogramming, Cancer Immunology, Structural Proteomics and Clinical Peptidomics).
About ICCVS
The International Centre for Cancer Vaccine Science (ICCVS) has been established in 2017 as a joint unit of the University of Gdańsk (UG) and the University of Edinburgh (UoE) within a project carried out within the International Research Agendas Programme of the Foundation for Polish Science funded from the European Regional Development Fund. The aim of ICCVS has been comprehensive research into development of novel diagnostic and prognostic markers and personalized anti-cancer therapies and vaccines, followed by their commercialization and implementation into clinical practice. ICCVS works on a range of national and international research projects concentrating on cancer biology and novel approaches to immunotherapies. The focus of the ICCVS is the development of personalized vaccine against non-small cell lung cancer (NSCLC). The approach is based on use of cancer specific T cells that are selected by the special algorithm elaborated at ICCVS. The first in vitro and in vivo studies are very encouraging, and the team plans to start clinical trials in a few years.
Research Field Technology » Biotechnology Education Level Master Degree or equivalent
Skills/Qualifications
Profile of candidates and requirements:
Specific Requirements
Key responsibilities include:
Languages ENGLISH Level Good
Eligibility criteria
Required documents:
Documents confirming academic degrees (a scan of master diploma or document stating the planned date of achieving which should not be later than 3 months from the date of announcement of this job offer)
NOTE: 1. Before signing the employment contract, the person selected in the competition is requested to submit to the University of Gdanskthe original of the diploma, in case of diplomas issued abroad. 2. Candidates holding a diploma awarded by a foreign higher education institution are required to provide a document confirming its recognition or equivalence in Poland, in accordance with applicable Polish regulations, prior to employment.
Selection process
Number of offers available 1 Company/Institute International Centre for Cancer Vaccine Science, University of Gdansk Country Poland State/Province pomorskie City Gdańsk Postal Code 80-809 Street Kładki 24 Geofield